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Abstract
Streptolysin O belongs to the class of thiol-activated toxins, which are single chain, four-domain proteins that bind to
membranes containing cholesterol and then assemble to form large oligomeric pores. Membrane binding involves a
conserved tryptophan-rich sequence motif located within the C-terminally located domain 4. In contrast, sites involved in
oligomerization and pore formation have been assigned to domains 1 and 3, respectively. We here examined the functional
properties of domain 4, which was recombinantly expressed with an N-terminal histidine tag for purification and an
additional cysteine residue for covalent labeling. The fluorescently labeled fragment readily bound to membranes, but it did
not form oligomers nor lyse cell membranes. Moreover, the labeled fragment did not detectably become incorporated into
hybrid oligomers when combined with lytically active full-length toxin. However, when present in large excess over the active
toxin, the domain 4 fragment effected reduction of hemolytic activity and of functional pore size, which indicates interference
with oligomerization of the lytically active species. Our findings support the notion that domain 4 of the streptolysin O
molecule may fold autonomously, is essential for membrane binding and is capable not of irreversible but of reversible
association with the entire toxin molecule. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Streptolysin O (SLO) is secreted by the Gram-pos-
itive bacterium Streptococcus pyogenes and belongs
to the highly homologous family of thiol-activated
cytolysins, which group of toxins is remarkable for
its strict speci¢city for membranes containing choles-
terol [1]. Binding to the sterol occurs at the level of
the monomer, whereas pore formation coincides with
the formation of large, ring-shaped, membrane-in-
serted oligomers of approx. 30 nm diameter [2].
Apart from these rings, arc-shaped oligomerization
intermediates have been characterized that constitute
pores of reduced functional size and are lined on the
facing side by a free edge of the target membrane
[2,3]. While the X-ray structure of the monomer
has been determined for one of the toxins (Fig. 1)
[4], crystallographic analysis of the pore oligomers
has been precluded by their extraordinarily large
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size and their heterogeneity. Nevertheless, it has
become clear that, among the four domains of the
monomeric molecule, the C-terminal domain 4 has
an essential role in membrane binding [5], while do-
mains 1 and 3 participate in oligomerization and
concomitant membrane permeabilization [6,7]. How-
ever, it has not been unequivocally determined
whether these functions can exclusively be assigned
to the respective domains in question. In the present
study, we posed the following questions. (1) Is do-
main 4 capable of membrane binding independently
of the rest of the toxin molecule? (2) Is domain 4
involved in the subsequent steps of oligomerization
and pore formation? The answers provided contrib-
ute to the understanding of structure-to-function re-
lationships of the thiol-activated toxins.
2. Materials and methods
2.1. Construction and puri¢cation of the SLO domain
4 fragment (r-d4)
The SLO gene region corresponding to domain 4
(amino acids 459^571) of the SLO gene was ampli-
¢ed by PCR. The 3P-PCR primer was designed to
hybridize downstream from the coding region, while
the 5P-primer (GAA ACA ACA GGT ACC GAG
TGC ACT AGT GG) corresponded to the boundary
of domains 3 and 4; the ¢rst two underlined nucleo-
tides served to introduce an unique Kpn1 site for use
in cloning, whereas the third one served to change
tyrosine 460 to cysteine in order to facilitate covalent
labeling of the recombinant protein. The unique wild
type cysteine residue of SLO at position 530 was
replaced by alanine, which mutation was derived
from plasmid pMK206 [8] that served as the tem-
plate in PCR. The PCR product was inserted into
the expression vector pQE-30 (Qiagen) to provide for
an N-terminal puri¢cation tag of six histidine resi-
dues. Liquid cultures of Escherichia coli strain TG1
transformed with the recombinant plasmid were
grown in LB medium and supplemented with IPTG
(0.5 mM) to induce protein expression. The cells
were harvested by centrifugation, resuspended with
20 mM Tris-HCl, 0.5 M NaCl (pH 8.0) and lysed
by ultrasonication (Branson probe soni¢er 250).
The inclusion bodies released by this procedure
were recovered by centrifugation (20 min,
30 000Ug) and washed three times by resuspension
with 20 mM Tris-HCl, 0.3 M NaCl, 2% Triton X-100
and centrifugation. They were then solubilized with
8 M urea, 20 mM Tris-HCl, 0.3 M NaCl (pH 8.0)
and applied to a chromatography column ¢lled with
Chelating Sepharose FF (Amersham Pharmacia)
which had been presaturated with NiCl2. The column
was washed with 8 M urea, 0.5 M NaCl, 0.1 M
sodium phosphate, 10 mM Tris, pH 8.0, and then
with the former bu¡er but adjusted to pH 6.3. Fi-
nally, the domain 4 fragment (hereafter referred to as
r-d4) was eluted with 8 M urea, 0.5 M NaCl, 50 mM
MES, pH 5.5. The eluate was recovered in fractions
that were analyzed for purity by SDS-PAGE.
The puri¢cation of several point mutants of strep-
tolysin O (C530A, N402C, and S101C) fused to mal-
tose-binding protein of E. coli has been described
previously [9].
2.2. Cysteine-speci¢c covalent labeling or chemical
cleavage
For covalent labeling with £uorescein maleimide
or tetramethylrhodamine maleimide (both from Mo-
lecular Probes, Eugene, OR), the r-d4 protein (1^2
mg) was ¢rst transferred by gel ¢ltration into 8 M
urea, 50 mM sodium phosphate, pH 7.5 using a
PD10 column (Amersham Pharmacia) and then sup-
plemented with the respective labeling reagent (dis-
solved in DMSO) to 0.5 mM. After incubation at
room temperature for 15 min, excess reagent was
removed by gel ¢ltration as above. Labeling yield
was estimated spectrophotometrically to v 90% with
£uorescein and to v 75% with tetramethylrhod-
amine, respectively, whereby the A280 of r-d4 was
determined from its amino acid sequence according
to [10]. The molar extinction coe⁄cients of the labels
(as stated by the supplier) were 83 000 M31 cm31 for
£uorescein and 91 000 M31 cm31 for tetramethyl-
rhodamine, respectively.
Cysteine-speci¢c chemical cleavage was carried out
according to [11] with minor modi¢cations. Labeling
with nitrothiocyanobenzoate (NTCB, 5 mM; Sigma)
was carried out for 60 min in 8 M urea, 50 mM Tris-
HCl, 1 mM EDTA, pH 7.5. The protein was then
immediately transferred by gel ¢ltration into 6 M
guanidine chloride, 0.1 M Tris-HCl, 1 mM EDTA,
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pH 9.0 and incubated at room temperature for 24 h.
The sample was then passed over Chelating Sephar-
ose FF to remove the cleaved histidine tag as well as
any uncleaved protein. The cleaved r-d4 protein de-
void of the histidine tag was collected with the £ow-
through, concentrated by ethanol precipitation and
redissolved with 8 M urea/50 mM sodium phosphate,
pH 7.5. Homogeneity of the cleaved protein was con-
¢rmed by Tris/Tricine-SDS-PAGE according to [12].
(Note that in all of the experiments described below
involving labeled or unlabeled r-d4, the histidine tag
was retained unless stated otherwise.)
2.3. Renaturation of r-d4
The unlabeled, labeled, or cleaved r-d4 protein,
dissolved in 8 M urea/50 mM sodium phosphate
(pH 7.5), was diluted into 50 vols. of 5 mM Tris-
HCl, 125 mM NaCl, 0.1% BSA, pH 9.0 and incu-
bated at room temperature for 10 min. These diluted
solutions were employed in all of the below experi-
ments relating to the biological activity of r-d4.
2.4. Assay of toxin binding to erythrocytes
100 Wl of £uorescein-labeled, renatured r-d4 were
added to 1.9 ml of 125 mM NaCl, 0,1% BSA, bu¡-
ered to pH 6.0 (with 50 mM MES), pH 7.0 (with 50
mM sodium phosphate), or pH 8.0 or 9.0 (with 50
mM Tris-HCl), respectively; the ¢nal concentration
of r-d4 was 1^2 Wg/ml. One half of each of these
samples were used to resuspend washed, pelleted hu-
man or rabbit erythrocytes to 5% ¢nal concentration.
Following incubation on ice for 10 min, the erythro-
cytes were pelleted again. The supernatants were
withdrawn, mixed with an equal volume of 0.2 M
sodium borate pH 9.2, and assayed for £uorescein
£uorescence, whereby the spare halves of the r-d4
dilutions that had not been incubated with erythro-
cytes served as references. For quantitating the e¡ect
of r-d4 upon binding of the entire streptolysin O
molecule, the non-lytic £uorescein derivative of the
point mutant N402C [13] was incubated with 5%
erythrocytes at 2.5 Wg/ml both in the absence and
in the presence of unlabeled r-d4 (2 Wg/ml ¢nal con-
centration, corresponding to a ¢vefold molar excess
over N402C). The extent of binding was quantitated
£uorimetrically as before.
2.5. Hemolysis and hemolysis inhibition assays
The r-d4 protein (unlabeled, labeled, or NTCB-
cleaved) was renatured and then admixed with an
equal volume of isotonic bu¡er varying in pH (see
above). From these solutions (which contained 10
Wg/ml of the respective derivative of r-d4), twofold
serial dilutions were prepared in a round bottom
microtiter plate, followed by addition to each well
of an equal volume of 2.5% rabbit or human eryth-
rocytes suspended in 5 mM sodium phosphate/125
mM NaCl, pH 7.0. Hemolysis or hemagglutination
titers were read visually after incubation at room
temperature for 30 min.
For hemolysis inhibition assays, twofold serial di-
lutions were prepared of the lytically active SLO mu-
tant C530A, starting with 8 Wg/ml. To each well of
one series, the renatured domain 4 fragment was
added to 10 Wg/ml, whereas a parallel series was
supplemented with bu¡er only. Finally, rabbit or hu-
man erythrocytes were added to 1%. Hemolysis was
evaluated after 30 min using a microplate ¢lter pho-
tometer set to an extinction wavelength of 620 nm.
2.6. Release of calcein and of tetramethylrhodamine-
dextran from resealed erythrocyte ghosts
Human red cells were lysed osmotically in the
cold, laden with calcein and tetramethylrhodamine-
dextran and resealed as described [3]. Two parallel
dilution series were prepared of the lytically active
SLO mutant C530A at pH 6.0. To each well of one
of these series, the renatured, unlabeled domain 4
fragment was added to 10 Wg/ml. Then, a constant
amount of the labeled ghosts was added. The sam-
ples were incubated at room temperature for 15 min
and then centrifuged for 3 min in a benchtop centri-
fuge. The supernatants were withdrawn and assayed
for calcein and rhodamine-dextran £uorescence as
described [3].
2.7. Fluorescence energy transfer assay of oligomer
formation
Samples (5 Wg each) of the domain 4 fragment
labeled with £uorescein and with tetramethylrhod-
amine, respectively, were mixed and then added
to osmotically lysed, washed human erythrocyte
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membranes (ghosts) and incubated for 15 min at
37‡C. The £uorescence excitation spectrum was ob-
tained between 460 and 560 nm in a SPEX Fluori-
max spectro£uorimeter in the ratio mode (emission
wavelength: 577 nm; band passes: 2.1 nm). Refer-
ence samples were prepared from either labeled spe-
cies alone plus ghosts. All spectra were subtracted
with a scattering blank containing ghosts only with-
out any labeled protein.
To assess incorporation of the domain 4 fragment
into hybrid oligomers with the entire toxin molecule,
the lytically active cysteine mutant S101C, labeled
with £uorescein, was admixed with the tetramethyl-
rhodamine-labeled domain 4 fragment at ¢vefold
molar excess prior to incubation with ghosts. Refer-
ence samples were prepared as above.
2.8. Analysis of oligomerization by density gradient
centrifugation
Human erythrocyte ghosts (100 Wl packed volume)
were suspended at pH 6.0 and incubated (37‡C, 15
min) with various combinations of £uorescein-la-
beled and unlabeled intact toxin species (see Section
3). They were then recovered by centrifugation, solu-
bilized by addition of sodium deoxycholate to 5%
¢nal concentration, and subjected to density gradient
centrifugation as described [14]. The gradients were
split into eight fractions of equal volumes, which
were diluted with 5 vols. sodium borate (50 mM,
pH 9.0)/0.25% SDS, incubated at 70‡C for 5 min
and assayed for £uorescein £uorescence (excitation
wavelength: 488 nm; emission wavelength: 520 nm).
3. Results
3.1. Refolding of the domain 4 fragment and its
binding to erythrocytes
The amino acid residues 461^571, corresponding
to the C-terminal domain 4 of the folded structure
C
Fig. 1. Structure of the streptolysin O monomer in solution
(based on the crystal structure of the homologous toxin perfrin-
golysin O [4]). (A) Folded structure. The four domains are
identi¢ed in the accompanying sketch. The ¢rst amino acid resi-
due covered by this structure corresponds to residue S101 of
streptolysin O. Residue C530 is the only cysteine of wild type
streptolysin O; with all the mutants employed in this study, it
was replaced with alanine which substitution does not a¡ect
lytic activity [8]. (B) Top: assignment of tertiary to primary
structure. Domain 4 comprises a contiguous stretch at the C-
terminus of the sequence. In contrast, domains 1^3 each consist
of two or more distantly located segments. X: the 100 N-termi-
nal amino acids of streptolysin O (which are not required for
lytic activity [9]) are not covered by the crystal structure. Mid-
dle: the recombinant fragment r-d4 corresponds to domain 4 of
streptolysin O, N-terminally extended by six histidines and a
unique cysteine residue. Bottom: the tryptic fragment T2 of
perfringolysin O (see Section 4) comprises domain 4 as well of
the adjacent parts of domains 1^3.
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of SLO (Fig. 1A), were recombinantly expressed with
a puri¢cation tag comprising six histidine residues
and an extra cysteine attached to its N-terminus
(Fig. 1B); this protein is hereafter referred to as
r-d4. When r-d4, thiol-speci¢cally labeled with £uo-
rescein, was diluted from 8 M urea into bu¡ers vary-
ing in pH, incubated at room temperature, and cen-
trifuged, most of the £uorescence was found to
precipitate at pH 9 7. In contrast, the £uorescence
was quantitatively recovered in the supernatant at
pH 9.0, indicating that under this condition the pro-
tein had escaped aggregation. The r-d4 fragment was
therefore initially renatured at pH 9 in all subsequent
experiments.
Binding of r-d4 to both human and rabbit eryth-
rocytes was maximal at pH 9 7 and decreased to-
ward higher pH values (Fig. 2A). When erythrocytes
were laden with r-d4 at pH 6, washed, and then
resuspended and incubated at pH 9, the major frac-
tion of r-d4 was recovered in the supernatant, indi-
cating that binding was reversible (data not shown).
At the modest concentrations of toxin employed in
these experiments, r-d4 did not interfere with mem-
brane binding of the full-size streptolysin O molecule
(Fig. 2B).
The r-d4 molecule was entirely devoid of hemolytic
activity, but it e¡ected agglutination of both human
and rabbit erythrocytes. Hemagglutination was abol-
ished upon removal of the histidine tag by cysteine-
speci¢c chemical cleavage (cf. Fig. 1B). Since this
cleavage method results in blocking of the cysteine
thiol group [11], the cleaved r-d4 could not easily be
labeled for the quantitation of binding. However, the
cleaved fragment shared with the unlabeled one the
ability to inhibit hemolysis (see below), which sug-
gests that it also retained the capability of binding to
membranes.
3.2. The domain 4 fragment inhibits hemolysis by
intact streptolysin O
We next examined the functional interaction be-
tween r-d4 and lytically active SLO molecules. To
this end, the hemolytic capability of the active SLO
mutant C530A was quantitated in the presence of
various amounts of r-d4. Fig. 3A shows that the
fragment inhibited the hemolytic activity of C530A
in a dose-dependent manner, suggesting interference
of r-d4 with the oligomerization of C530A. The pH
dependence of this inhibitory action paralleled that
of membrane binding (data not shown), which sug-
gests that inhibition of hemolysis requires prior
membrane binding of r-d4. To further characterize
the in£uence of r-d4 upon oligomerization, r-d4
and C530A were then also applied to resealed eryth-
rocyte ghosts that had been laden with two soluble
markers of di¡erent size (calcein, Mr 622, and tetra-
methylrhodamine-dextran, Mr 64 000). When C530A
was applied alone, the e¡usion of dextran ceased
more readily with increasing dilution of the toxin
than the release of calcein (Fig. 3B). This was con-
sistent with previous results and with the existence of
incomplete, arc-shaped toxin oligomers creating
pores of reduced functional diameter and preferably
Fig. 2. Binding of recombinant domain 4 (r-d4) to erythrocytes.
(A) Fluorescein-labeled r-d4 was renatured by dilution at pH
9.0 and then incubated with rabbit or human erythrocytes at
various pH values. Binding was then quantitated £uorimetri-
cally by its depletion from the supernatant. (B) Unlabeled r-d4
was renatured, admixed at ¢vefold molar excess with the £uo-
rescein-labeled, non-lytic point mutant N402C, and incubated
with erythrocytes. Binding of N402C was quantitated as above.
(All values represent means of triplicates.)
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being detected at limiting concentrations of toxin.
While the release of either marker was readily re-
duced by the inclusion of r-d4 (10 Wg/ml), this inhib-
itory e¡ect commenced at higher concentrations of
C530A with the dextran than with calcein. The en-
hanced discrimination in the release of the two
markers suggests that r-d4 e¡ected a gradual reduc-
tion in size of the pores and, by inference, of the
oligomers formed by C530A. These ¢ndings there-
fore constitute additional evidence that r-d4 inter-
feres with oligomerization.
3.3. The domain 4 fragment does not oligomerize on
membranes
Despite its lack of hemolytic activity, the domain 4
fragment might still form oligomers on membranes,
as exempli¢ed by non-lytic mutants of other pore-
forming toxins [15]. In order to examine whether
r-d4 would form such non-lytic oligomers, the frag-
ment was thiol-speci¢cally labeled with £uorescein
and with tetramethylrhodamine, respectively. When
located close to one another, these two labels form
an e⁄cient couple for £uorescence energy transfer.
Mixing of the two labeled species prior to incubation
with the membranes should result in the formation
of mixed oligomers and, therefore, in the enhance-
ment of tetramethylrhodamine £uorescence upon ex-
citation of £uorescein due to energy transfer. This,
Fig. 4. Analysis of oligomerization of r-d4 by £uorescence en-
ergy transfer. The r-d4 protein, labeled with £uorescein (F) or
tetramethylrhodamine (R), was incubated with washed erythro-
cyte membranes, and £uorescence excitation spectra were ob-
tained (emission wavelength: 577 nm). The two labeled species
were admixed and then incubated with membranes. The ensuing
spectrum (Mixed sample) is congruent with F+R, the numerical
sum of he individual samples F and R, indicating lack of en-
ergy transfer.
Fig. 3. E¡ect of r-d4 upon membrane permeabilization by the
lytically active mutant C530A. (A) Inhibition of hemolysis. Seri-
al twofold dilutions of C530A were supplemented with r-d4 at
the amounts indicated. Rabbit erythrocytes were added, and the
amount of cells remaining unlysed after incubation for 30 min
was quantitated by absorbance at 620 nm. (B) Release of £uo-
rescent markers of di¡erent size. Calcein (Mr 620) and tetra-
methylrhodamine-dextran (Mr 64 000) were simultaneously in-
cluded within resealed erythrocyte ghosts, which were exposed
to serial dilutions of C530A, either with or without supplemen-
tation by r-d4 (10 Wg/ml). The release of either marker was
quantitated £uorimetrically.
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however, was not observed: the excitation spectrum
of £uorescence detected at 577 nm (representing the
emission maximum of the rhodamine-labeled species)
obtained with such a mixed sample corresponded
exactly to the sum of the two spectra recorded with
the individual components (Fig. 4). This result indi-
cates that r-d4 lacks oligomerizing capability.
In a second experimental approach, the mem-
branes were incubated with £uorescein-labeled r-d4,
solubilized with the detergent deoxycholate, and the
oligomeric state of the protein examined by density
gradient centrifugation. Fig. 5 shows that r-d4 was
recovered with the top fractions of the gradients,
indicative of a state of low molecular weight. In con-
trast, the lytically active point mutant S101C was
recovered from the bottom fractions, re£ecting its
conversion into large oligomers upon contact with
membranes. Oligomerization of S101C persisted in
the presence of unlabeled r-d4, i.e. the fragment
had no detectable inhibitory e¡ect at the high toxin
concentrations employed in this experiment. Impor-
tantly, when £uorescently labeled r-d4 was combined
with the unlabeled, lytically active SLO point mutant
C530A, no £uorescence was detected in the bottom
fractions, indicating that the labeled fragment had
failed to enter into hybrid oligomers with the active
species. The latter conclusion was then con¢rmed by
the above £uorescence energy transfer approach,
which failed to detect any energy transfer from the
£uorescein-labeled active mutant S101C to rhod-
amine-labeled r-d4 upon co-incubation with mem-
branes (data not shown). In sum, the experiments
did not yield any evidence of stable association of
the r-d4 fragment, neither with itself nor with full-
length SLO molecules.
4. Discussion
The elongated, four-domain molecular structure of
the thiol-activated toxins was initially characterized
by electron microscopy and hydrodynamic analysis
[16], but only from the crystal structure [4] it has
become clear that the membrane-binding domain is
formed by a contiguous C-terminal part of the pro-
tein sequence. In contrast, the polypeptide chain runs
back and forth through the residual three domains,
each of which therefore comprises several shorter
segments scattered along the sequence (cf. Fig. 1B).
Thus, if the molecule is proteolytically cleaved in the
middle and the two ensuing fragments are separated,
only domain 4 will remain intact, whereas domains
1^3 will be split apart. Accordingly, in two earlier
studies, an N-terminal tryptic fragment of perfringo-
lysin (named T1) was found to be devoid of any
detectable activity, whereas the C-terminal T2 frag-
ment retained the activity of binding to membranes
and of interfering with the oligomerization of func-
tionally active, intact toxin [17,18]. The question now
arose whether or not both of these partial activities
of the T2 fragment could be ascribed to its domain 4
section. The ¢ndings of the present study indicate
that this is indeed the case, although the interference
with oligomerization of wild type toxin appears to be
less pronounced with the streptolysin O r-d4 frag-
ment. Reportedly, the hemolytic activity of the cor-
responding wild type perfringolysin molecule was
entirely abrogated by T2 when the latter was present
in su⁄cient excess [18]. In contrast, with r-d4, hemol-
ysis by intact streptolysin O was diminished but not
entirely abolished. The apparently lower inhibitory
activity of r-d4 as compared to T2 might conceiv-
ably arise by its lack of the elements derived from
Fig. 5. Analysis of oligomerization of r-d4 by density gradient
centrifugation. Fluorescein-labeled streptolysin O mutants were
incubated with erythrocyte membranes. The samples were solu-
bilized with sodium deoxycholate, placed on top of sucrose den-
sity gradients, and subjected to ultracentrifugation. The active
mutant S101C is recovered from the bottom fractions, indicat-
ing its transformation into oligomers upon contact with mem-
branes. In contrast, £uorescein-labeled r-d4 is recovered from
the bottom fractions, which indicates lack of oligomerization.
The labeled r-d4 also failed to be incorporated into hybrids
with the unlabeled active mutant C530A.
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domains 1^3. Alternatively, the di¡erence in inhibi-
tory e⁄cacy might be due to intrinsic di¡erences of
the two homologous but still distinct toxins. In any
event, T2 and r-d4 apparently share the same mode
of action. Both of them fail to form stable oligomers
on their own. While the possibility of stable integra-
tion into hybrid oligomers with intact toxin was not
de¢nitely addressed with T2 [18], we here found that
no such stable interaction occurred with r-d4. Never-
theless, both fragments clearly interfere with oligo-
merization of the wild type molecules, which was
shown by a reduced oligomer average size in the
case of T2 and, more indirectly, by the reduction
of pore size due to r-d4. In the absence of irreversible
association of r-d4 with the intact toxin molecules,
the most likely mode of this inhibitory e¡ect appears
to consist in its reversible interaction with monomers
or growing oligomers of intact streptolysin O.
An interesting fortuitous ¢nding consists in the
agglutination of erythrocytes depending on the N-
terminal histidine tag of r-d4. This non-speci¢c e¡ect
may be expected also to arise in the case of other
membrane-binding proteins when recombinantly ex-
pressed as histidine-tagged fusions. Even in the ab-
sence of speci¢c binding, the histidine tag may confer
a non-speci¢c interaction with erythrocyte mem-
branes upon proteins intended to remain soluble.
To e¡ect agglutination, the histidine tag will have
to protrude from the speci¢cally bound membrane,
which in the case of streptolysin O means that the N-
terminal part of domain 4 does neither insert nor
closely approach the target lipid bilayer. From the
inhibition of intact streptolysin O by the membrane-
bound fragment, it would then appear that the intact
molecule attains a similar orientation with respect to
the membrane, so that we hypothesize that also with-
in the membrane-bound intact toxin molecule the N-
terminal part of domain 4 remains located remotely
from the lipid bilayer.
In sum, our study shows that domain 4 of strep-
tolysin O is an autonomously folding unit, that it
binds to membranes independently of the rest of
the molecule, and that it associates with lytically ac-
tive toxin molecules in an abortive, reversible fashion
that nevertheless points to a role of this domain in
the formation of the pore oligomer. These ¢ndings
signify a more stringent assignment of function to
parts of the structure than hitherto derived with pro-
teolytic fragments and point mutants.
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